Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.